<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087968</url>
  </required_header>
  <id_info>
    <org_study_id>HepQuant-002-2124</org_study_id>
    <nct_id>NCT03087968</nct_id>
  </id_info>
  <brief_title>Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124</brief_title>
  <official_title>Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HepQuant, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HepQuant, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical investigation is a substudy within GS-US-416-2124, IND 129570, which is A Phase
      2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of
      GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe
      Alcoholic Hepatitis. The use of the HepQuant SHUNT test is to assess liver disease severity
      before, during, and after treatment with GS-4997 or placebo, to assess liver disease
      severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main study is a Phase 2, double blind, proof-of-concept, randomized study evaluating the
      safety, tolerability, and biological activity of GS-4997 in combination with prednisolone,
      compared to prednisolone alone, in subjects with severe, histologically-confirmed AH.

      This substudy uses the HepQuant SHUNT Liver Diagnostic test to assess severity of disease at
      baseline and to track disease progression or improvement over the 24 weeks of the study. The
      HepQuant SHUNT test will be performed at baseline (Day 1) and at Weeks 1, 2, 4, 12, and 24
      regardless of treatment Arm.

      GS-4997 Dose and Mode of Administration. Subjects will be randomized 1:1 to either:

        -  Treatment Group A: GS-4997 18 mg (1 x 18 mg tablet) AND prednisolone 40 mg (4 x 10 mg
           tablets), both administered orally once daily

        -  Treatment Group B: GS-4997 placebo (1 tablet) AND prednisolone 40 mg (4 x 10 mg
           tablets), both administered orally once daily
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No longer a sub-study - Changing to an independent parallel study
  </why_stopped>
  <start_date type="Anticipated">July 31, 2016</start_date>
  <completion_date type="Actual">September 13, 2017</completion_date>
  <primary_completion_date type="Actual">September 13, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the change in (DSI ) Disease Severity Index between GS-4997 treatment and placebo arms</measure>
    <time_frame>HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24</time_frame>
    <description>Using the SHUNT DSI to evaluate the liver, this outcome will compare the two arms to determine if SHUNT DSI is able to measure a change between the experimental and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 1</measure>
    <time_frame>HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24</time_frame>
    <description>To determine the relationship of baseline Disease Severity Index (DSI) to mortality risk;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 2</measure>
    <time_frame>HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24</time_frame>
    <description>To determine the relationship of change in Disease Severity Index (DSI) to mortality risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 3</measure>
    <time_frame>HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24</time_frame>
    <description>To correlate baseline Disease Severity Index (DSI) with baseline Maddrey, MELD, and Lille scorestest with the pharmacokinetics of GS-4997</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 4</measure>
    <time_frame>HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24</time_frame>
    <description>To determine the relationship between baseline Disease Severity Index (DSI), Maddrey, MELD, and Lille scores and mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Severe Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>GS-4997 + Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-4997 + Prednisolone for 28 days
HepQuant SHUNT Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Prednisolone for 28 days
HepQuant SHUNT Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-4997</intervention_name>
    <description>Experimental drug</description>
    <arm_group_label>GS-4997 + Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.</description>
    <arm_group_label>GS-4997 + Prednisolone</arm_group_label>
    <arm_group_label>Prednisolone + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HepQuant SHUNT Test</intervention_name>
    <description>The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.
For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples.</description>
    <arm_group_label>GS-4997 + Prednisolone</arm_group_label>
    <arm_group_label>Prednisolone + Placebo</arm_group_label>
    <other_name>SHUNT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Prednisolone + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to give informed consent prior to any study specific procedures being
             performed. In individuals with hepatic encephalopathy (HE) which may impair
             decision-making, consent will be obtained per hospital procedures (eg, by Legally
             Authorized Representative)

          2. Clinical diagnosis of severe AH

          3. Maddrey's DF ≥ 32 at screening

        Exclusion Criteria:

        Key Exclusion Criteria:

          1. Pregnant or lactating females;

          2. Other causes of liver disease including chronic hepatitis B (hepatitis B surface
             antigen [HBsAg] positive), chronic hepatitis C (HCV RNA positive), acetaminophen
             hepatotoxicity, biliary obstruction, and autoimmune liver disease;

          3. Serum AST &gt;400 U/L or ALT &gt;300 U/L;

          4. MELD &gt;30 at screening;

          5. Maddrey's DF &gt;60 at screening;

          6. Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria;

          7. Concomitant or previous history of hepatocellular carcinoma;

          8. History of liver transplantation;

          9. HIV Ab positive;

         10. Clinical suspicion of pneumonia;

         11. Uncontrolled sepsis;

         12. Uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of
             screening that was associated with shock or required transfusion of more than 3 units
             of blood;

         13. Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine &gt;221
             μmol/L (&gt;2.5 mg/dL) or the requirement for renal replacement therapy;

         14. Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory
             support (ie, endotracheal intubation or positive-pressure ventilation);

         15. Portal vein thrombosis;

         16. Acute pancreatitis;

         17. Cessation of alcohol consumption for more than 2 months before Baseline/ Day 1 NOTE:
             Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Everson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HepQuant, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Newport Newes</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

